Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Cancer Discov. 2019 May 20;9(8):1064–1079. doi: 10.1158/2159-8290.CD-19-0182

Figure 1. TAS-120 is clinically effective in FGFR2 fusion-positive ICC patients whose tumors acquired resistance to BGJ398 or Debio1347.

Figure 1.

A, Radiologic scans of patients 1–4 during the course of FGFR inhibitor therapy.

B-D, ddPCR analysis of serial ctDNA samples from patients 1–3. Time periods of therapy with the specific FGFR inhibitors are indicated by shading. MAF: mutant allele frequency. Mutations identified in tumor biopsies taken at the indicated times are presented at the bottom of each graph. CCF: cancer cell fraction.